# Nomic Bio

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/nomic-bio

- Industry: Biotechnology
- Headquarters: Montreal, Canada
- Website: www.nomic.bio/
- Total disclosed funding: $59M
- Latest round: Series B (Sep 17, 2024)
- Investors on record: 6

## About

Nomic Bio, based in Canada, specializes in high-throughput proteomics, providing advanced solutions for protein analysis and immunoassay technology.Founded in 2018 in Montreal, Canada, Nomic Bio focuses on innovative proteomics solutions. The company has successfully raised USD 42.00 mn in its recent Series B funding round on September 17, 2024, with investments from prominent firms including Amplitude and Avant Bio. The leadership team is headed by CEO Milad Dagher, who, alongside co-founders Arya Tavakoli and Jeff Munzar, has been instrumental in the company's development. Nomic Bio has completed a total of 5 deals to date, positioning itself in the competitive biotech landscape.Nomic Bio offers high-throughput proteomics services centered around its flagship product, the nELISA, which utilizes DNA nanotechnology for scalable profiling of approximately 275 cytokines. This innovative approach allows clients to conduct flexible multiplexing of proteins, which is essential for understanding protein expression and interactions in various research contexts. The company serves a global clientele, including research institutions and pharmaceutical firms across North America, Europe, and Asia, fulfilling the growing need for precise and rapid proteomics solutions in drug discovery and disease research.The primary revenue stream for Nomic Bio comes from its nELISA services, which cater to B2B clients in the pharmaceutical and biotechnology sectors. The service model allows clients to submit samples for protein profiling, with typical turnaround times of one week. Pricing is variable, tailored to the specific requirements of each client, and the company also provides subscription-based access to its platform for ongoing collaborations. This model fosters long-term relationships with clients, facilitating continued access and utilization of Nomic Bio's proteomics technologies.Nomic Bio plans to leverage the USD 42.00 mn raised in its Series B funding to enhance its product offerings and expand into new geographic markets. The company aims to develop new products that build on its existing nELISA technology, with a focus on addressing evolving market demands. Specific regions targeted for expansion include Europe and Asia, with initiatives set to roll out in the coming years, further establishing Nomic Bio's presence in the global proteomics market.

## Funding rounds

- Series B, Sep 17, 2024, $42M — SR One, Lux Capital, Real Ventures, Amplitude, Avant Bio
- Series A, Dec 8, 2021, $17M — SR One, Lux Capital, Casdin Capital

## Investors

- SR One (https://capitalatlas.ai/funds/sr-one) — Series A, Series B
- Lux Capital (https://capitalatlas.ai/funds/lux-capital) — Series A, Series B
- Casdin Capital (https://capitalatlas.ai/funds/casdin-capital) — Series A
- Real Ventures — Series B
- Amplitude (https://capitalatlas.ai/funds/amplitude) — Series B
- Avant Bio (https://capitalatlas.ai/funds/avant-bio) — Series B